[Form 4] Insmed, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions. The filings show 20,193 shares sold at a weighted-average price of $127.42 (range $127.00–$127.99) and 4,807 shares sold at a weighted-average price of $128.27 (range $128.00–$128.72). After these sales, the report lists beneficial ownership of 110,444 shares in one line and 105,637 shares in another line, each reported as direct ownership. The Form 4 was signed via power of attorney.

Positive

• Detailed trade disclosure with weighted-average prices and price ranges provided for both sale blocks
• Post-transaction direct ownership remains substantial (reported above 100,000 shares), indicating ongoing insider stake

Negative

• Insider sales of 25,000 shares could be viewed unfavorably by some investors despite being routine
• No explanation in the filing for the reason for the sales beyond the required transaction details

Insights

Corporate Governance Expert

TL;DR: COO sold 25,000 shares in two blocks at ~$127–$128; ownership remains six-figure and is reported as direct.

The filing documents routine Section 16 reporting for officer stock sales rather than issuance or option exercise. The transaction is described as sales with specified price ranges and weighted-average prices; the reporting person retains substantial direct holdings after the trades. From a governance perspective, these are standard disclosures showing liquidity actions by an insider and use of a power of attorney signature.

Securities Analyst

TL;DR: Insider sold 25,000 shares at weighted averages of $127.42 and $128.27; remaining direct holdings exceed 100,000 shares.

The Form 4 provides explicit quantities and price ranges for sales executed on 08/19/2025, enabling verification of insider activity. The reported post-sale beneficial ownership figures indicate the insider still holds a material stake. There are no derivative transactions reported. The disclosure supplies sufficient granularity for trade size and price range inquiries.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adsett Roger

(Last) (First) (Middle)

700 US HIGHWAY 202/206

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		20,193	D	$127.42(1)	110,444	D
Common Stock	08/19/2025		S		4,807	D	$128.27(2)	105,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is the weighted average sales price representing 20,193 shares sold at prices ranging from $127.00 to $127.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

2. This is the weighted average sales price representing 4,807 shares sold at prices ranging from $128.00 to $128.72 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Roger Adsett, by Michael A. Smith as Attorney-in-fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Insmed (INSM) insider Roger Adsett report on Form 4?

He reported selling a total of 25,000 shares of Insmed common stock in two transactions on 08/19/2025 with weighted-average prices of $127.42 and $128.27.

How many shares did Roger Adsett sell and at what price ranges?

20,193 shares sold at prices ranging $127.00–$127.99 (weighted avg $127.42) and 4,807 shares sold at $128.00–$128.72 (weighted avg $128.27).

What was Roger Adsett's beneficial ownership after the reported sales?

The Form 4 reports 110,444 shares and 105,637 shares on separate report lines, each listed as direct beneficial ownership following the transactions.

Were any derivative securities reported in this Form 4 for INSM?

No derivative securities (options, warrants, convertible securities) are reported in Table II of this filing.

Who signed the Form 4 for Roger Adsett?

The Form 4 is signed /s/ Roger Adsett, by Michael A. Smith as Attorney-in-fact, indicating a power of attorney was used for signature.